Iasibon

Ibandronic Acid, the active ingredient in Iasibon, is a bisphosphonate presented as an injectable solution for intravenous use. It treats osteoporosis and Paget's disease of bone in adults.\n\nGNH India supplies Iasibon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibandronic Acid is a bisphosphonate that acts on bone‑remodelling disorders.\n\nOsteoporosis: reduces the risk of vertebral and hip fractures by increasing bone mineral density.\nPaget's disease of bone: normalises bone turnover and alleviates bone pain.\nSteroid‑induced osteoporosis: helps maintain bone density in patients receiving long‑term glucocorticoids.

Common Side Effects:\n- Flu‑like symptoms such as fever, chills, and myalgia.\n- Nausea or vomiting.\n- Headache or dizziness.\n- Transient elevation of serum transaminases.\n\nSerious or Rare Side Effects:\n- Acute phase reaction with severe fever and hypotension.\n- Renal impairment or acute kidney injury.\n- Atrial fibrillation or other cardiac arrhythmias.\n- Osteonecrosis of the jaw, especially after dental procedures.\n- Severe hypocalcaemia requiring emergency treatment.\n- Anaphylactic or severe allergic reactions.

Before initiating therapy, evaluate renal function and correct calcium/vitamin D status.\n\nRenal function: assess baseline creatinine clearance and avoid use in severe impairment.\nCalcium/Vit D status: ensure normal serum calcium and adequate vitamin D supplementation.\nHypocalcaemia: monitor serum calcium before and after infusion.\nConcurrent bisphosphonates: avoid overlapping therapy to reduce cumulative toxicity.\nPregnancy and lactation: contraindicated unless benefits clearly outweigh risks.\nStore at ambient temperature: keep in original container, protect from light and moisture.

Ibandronic Acid may interact with several medicines.\n\nMajor Interactions (Avoid):\n- Aminoglycosides: increased risk of nephrotoxicity.\n- Loop diuretics: may exacerbate hypocalcaemia.\n- Concurrent intravenous bisphosphonates: additive bone toxicity.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: monitor renal function during co‑administration.\n- Systemic corticosteroids: heightened risk of hypocalcaemia, check calcium levels.\n- Vitamin D analogues: adjust dosing and monitor calcium to avoid hyper‑ or hypocalcaemia.